Performance of the Abbott RealTime high-risk HPV test in women with abnormal cervical cytology smears

Journal of Medical Virology

Volumn 82, Issue 7, 2010, Pages 1186-1191

  Cuzick, Jack ^a   Ambroisine, Laurence ^a   Cadman, Louise ^a   Austin, Janet ^a   Ho, Linda ^a   Terry, George ^a   Liddle, Stuart ^b   Dina, Roberto ^c   McCarthy, Julie ^d   Buckley, Hilary ^d   Bergeron, Christine ^e   Soutter, W P ^c   Lyons, Deirdre ^d   Szarewski, Anne ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b Doctors Laboratory   (United Kingdom)

^c QUEEN CHARLOTTE S AND CHELSEA HOSPITAL   (United Kingdom)

^d ST MARY S HOSPITAL   (United Kingdom)

^e LABORATOIRE CERBA   (France)

Author keywords

Abbott RealTime high risk HPV test; Cervical screening; HPV testing; Sensitivity; Specificity

Indexed keywords

ADULT; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC TEST; FEMALE; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; NONHUMAN; SENSITIVITY ANALYSIS; SENSITIVITY AND SPECIFICITY; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; WART VIRUS; COMPARATIVE STUDY; COMPLICATION; DIFFERENTIAL DIAGNOSIS; EVALUATION STUDY; GENETICS; ISOLATION AND PURIFICATION; PAPILLOMAVIRUS INFECTIONS; PATHOLOGY; POLYMERASE CHAIN REACTION; PROCEDURES; UTERINE CERVICAL NEOPLASMS; UTERINE CERVIX; VAGINA SMEAR; VIROLOGY;

HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPE 16;

VIRUS DNA;

CERVIX UTERI; DIAGNOSIS, DIFFERENTIAL; DNA, VIRAL; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; PAPILLOMAVIRUS INFECTIONS; POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 77954405192     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.21801     Document Type: Article

References (14)

1. Almonte M, Ferreccio C, Winkler J, Cuzick J, Tsu V, Robles S, Takahashi R, Sasieni P. 2007. Cervical screening by visual inspection, HPV testing, liquid-based and conventional cytology in Amazonian Peru. Int J Cancer 121:796-802.
2. Bulkmans NW, Rozendaal L, Voorhorst FJ, Snijders PJ, Meijer CJ. 2005. Long-term protective effect of high risk human papillomavirus testing in population-based cervical screening. Br J Cancer 92:1800-1802.
3. Bulkmans NW, Berkhof J, Rozendaal L, van Kemenade FJ, Boeke AJ, Bulk S, Voorhorst FJ, Verheijen RH, van Groningen K, Boon ME, Ruitinga W, van Ballegooijen M, Snijders PJ, Meijer CJ. 2007. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-Year follow-up of a randomised controlled implementation trial. Lancet 370:1764-1772.
4. Cuzick J, Szarewski A, Cubie H, Hulman G, Kitchener H, Luesley D, McGoogan E, Menon U, Terry G, Edwards R, Brooks C, Desai M, Gie C, Ho L, Jacobs I, Pickles C, Sasieni P. 2003. Management of women who test positive for high risk types of human papillomavirus: The HART study. Lancet 362:1871-1876.
5. Cuzick J, Clavel C, Petry KU, Meijer CJ, Hoyer H, Ratnam S, Szarewski A, Birembaut P, Kulasingam S, Sasieni P, Iftner T. 2006. Overview of the European and North American studies on HPV testing in primary cervical screening. Int J Cancer 119:1095-1101.
6. Cuzick J, Szarewski A, Mesher D, Cadman L, Austin J, Perryman K, Ho L, Terry G, Sasieni P, Dina R, Soutter WP. 2008. Long-term follow-up of cervical abnormalities among women screened by HPV testing and cytology - Results from the Hammersmith study. Int J Cancer 122:2294-2300.
7. Dillner J, Rebolj M, Birembaut P, Petry KU, Szarewski A, Munk C, de Sanjose S, Naucler P, Lloveras B, Kjaer S, Cuzick J, van Ballegooijen M, Clavel C, Iftner T, Joint European Cohort Study. 2008. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: Joint European cohort study. Br Med J 337:a1754.
8. Khan MJ, Castle PE, Lorincz AT, Wacholder S, Sherman M, Scott DR, Rush BB, Glass AG, Schiffman M. 2005. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst 97: 10729.
9. Kotaniemi-Talonen L, Anttila A, Malila N, Tarkkanen J, Laurila P, Hakama M, Nieminen P. 2008. Screening with a primary human papillomavirus test does not increase detection of cervical cancer and intraepithelial neoplasia 3. Eur J Cancer 44:565-571.
10. Mayrand MH, Duarte-Franco E, Rodrigues I, Walter SD, Hanley J, Ferenczy A, Ratnam S, Coutlée F, Franco EL. 2007. Canadian Cervical Cancer Screening Trial Study Group. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med 357:1579-1588.
11. Naucler P, Ryd W, Törnberg S, Strand A, Wadell G, Elfgren K, Rådberg T, Strander B, Forslund O, Hansson BG, Rylander E, Dillner J. 2007. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med 357:1589-1597.
12. Ronco G, Giorgi-Rossi P, Carozzi F, Confortini M, Dalla Palma P, Del Mistro A, Gillio-Tos A, Minucci D, Naldoni C, Rizzolo R, Schincaglia P, Volante R, Zappa M, Zorzi M, Cuzick J, Segnan N. 2008. New technologies for Cervical Cancer Screening Working Group. Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alonewith conventional cytology as the primary cervical cancer screening test. J Natl Cancer Inst 100:492-501.
13. Szarewski A, Ambroisine L, Cadman L, Austin J,Ho L, Terry G, Liddle S, Dina R, McCarthy J, Buckley H, Bergeron C, Soutter P, Lyons D, Cuzick J. 2008. Comparison of predictors for high-grade cervical intraepithelial neoplasia in women with abnormal smears. Cancer Epidemiol Biomarkers Prev 17:3033-3042.
14. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Muñoz N. 1999. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189:12-19. (Pubitemid 29406813)